



MOZAMBIQUE

Number of new cases

26 578

Number of deaths

19 020

Number of prevalent cases (5-year)

49 607


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	16 099 642	16 989 821	33 089 463
Incidence*			
Number of new cancer cases	10 219	16 359	26 578
Age-standardized incidence rate	115.4	141.4	128.8
Risk of developing cancer before the age of 75 years (cum. risk %)	11.5	13.1	12.3
Top 3 leading cancers (ranked by cases)**	Kaposi sarcoma Prostate Liver	Cervix uteri Breast Kaposi sarcoma	Cervix uteri Kaposi sarcoma Breast
Mortality*			
Number of cancer deaths	7 391	11 629	19 020
Age-standardized mortality rate	87.3	104.8	96.3
Risk of dying from cancer before the age of 75 years (cum. risk %)	8.7	10.2	9.5
Top 3 leading cancers (ranked by deaths)**	Kaposi sarcoma Prostate Liver	Cervix uteri Breast Oesophagus	Cervix uteri Kaposi sarcoma Liver
Prevalence*			
5-year prevalent cases	17 881	31 726	49 607



Top 5 most frequent cancers**


Males



Rank	Cancer site	Number of cases	Percent
1st	Kaposi sarcoma	2 616	25.6%
2nd	Prostate	1 556	15.2%
3rd	Liver	872	8.5%
4th	NHL	627	6.1%
5th	Oesophagus	571	5.6%
-	Others	3 977	38.9%

Number of new cases in 2022, males, all ages


Females



Rank	Cancer site	Number of cases	Percent
1st	Cervix uteri	5 456	33.4%
2nd	Breast	2 048	12.5%
3rd	Kaposi sarcoma	1 373	8.4%
4th	Oesophagus	954	5.8%
5th	Liver	784	4.8%
-	Others	5 744	35.1%

Number of new cases in 2022, females, all ages

Both sexes



Rank	Cancer site	Number of cases	Percent
1st	Cervix uteri	5 456	20.5%
2nd	Kaposi sarcoma	3 989	15.0%
3rd	Breast	2 048	7.7%
4th	Liver	1 656	6.2%
5th	Prostate	1 556	5.9%
-	Others	11 873	44.7%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Cervix uteri	5 456	1	20.5	4.7	4 000	1	21.0	3.8	11 190	22.6
Kaposi sarcoma	3 989	2	15.0	1.2	2 580	2	13.6	0.75	6 954	14.0
Breast	2 048	3	7.7	2.0	1 207	5	6.3	1.2	3 944	8.0
Liver	1 656	4	6.2	0.81	1 488	3	7.8	0.77	2 956	6.0
Prostate	1 556	5	5.9	3.5	1 037	6	5.5	2.2	2 263	4.6
Oesophagus	1 525	6	5.7	1.0	1 428	4	7.5	0.99	2 537	5.1
NHL	1 367	7	5.1	0.48	990	7	5.2	0.38	2 876	5.8
Bladder	878	8	3.3	0.64	540	8	2.8	0.40	1 655	3.3
Colorectum	651	9	2.4	0.43	492	9	2.6	0.33	1 126	2.3
Leukaemia	515	10	1.9	0.14	374	10	2.0	0.13	1 057	2.1
Vulva	266	11	1.0	0.21	158	13	0.83	0.15	573	1.2
Kidney	250	12	0.94	0.05	169	12	0.89	0.04	557	1.1
Lip, oral cavity	240	13	0.90	0.13	156	14	0.82	0.09	502	1.0
Lung	210	14	0.79	0.15	205	11	1.1	0.15	333	0.67
Ovary	197	15	0.74	0.21	127	16	0.67	0.17	382	0.77
Hodgkin lymphoma	179	16	0.67	0.05	93	19	0.49	0.03	413	0.83
Thyroid	178	17	0.67	0.08	47	25	0.25	0.03	379	0.76
Corpus uteri	151	18	0.57	0.21	64	22	0.34	0.07	310	0.63
Pancreas	140	19	0.53	0.09	130	15	0.68	0.09	182	0.37
Penis	136	20	0.51	0.17	67	21	0.35	0.09	268	0.54
Melanoma	129	21	0.49	0.09	47	25	0.25	0.04	290	0.59
Stomach	126	22	0.47	0.09	115	17	0.61	0.08	177	0.36
Brain CNS	111	23	0.42	0.03	96	18	0.51	0.03	256	0.52
Oropharynx	110	24	0.41	0.05	81	20	0.43	0.04	259	0.52
Salivary glands	93	25	0.35	0.03	61	23	0.32	0.02	209	0.42
Larynx	76	26	0.29	0.05	51	24	0.27	0.04	189	0.38
Multiple myeloma	50	27	0.19	0.03	39	27	0.21	0.03	97	0.20
Vagina	48	28	0.18	0.03	26	28	0.14	0.02	88	0.18
Testis	31	29	0.12	0.02	17	29	0.09	0.01	70	0.14
Nasopharynx	13	30	0.05	0.00	9	31	0.05	0.00	26	0.05
Mesothelioma	10	31	0.04	0.00	10	30	0.05	0.00	20	0.04
Hypopharynx	9	32	0.03	0.01	6	33	0.03	0.00	14	0.03
All cancers	26 578	-	-	12.3	19 020	-	-	9.5	49 607	-
All cancers excl. NMSC	25 741	-	-	12.0	18 723	-	-	9.3	47 727	-

Data source and methods

Incidence



Country-specific data source: Beira cancer registry, Maputo cancer registry
Method: Weighted/simple average of the most recent sub-national rates applied to 2022 population

Mortality

Country-specific data source: No data
Method: Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011–2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

